What is William Blair’s Estimate for CNTX FY2025 Earnings?

Context Therapeutics Inc. (NASDAQ:CNTX) – Equities research analysts at William Blair upped their FY2025 earnings per share (EPS) estimates for Context Therapeutics in a research note issued on Wednesday, May 7th. William Blair analyst M. Phipps now expects that the company will earn ($0.24) per share for the year, up from their previous estimate of ($0.26). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. William Blair also issued estimates for Context Therapeutics’ Q4 2025 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at ($0.50) EPS.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05).

A number of other equities research analysts have also weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Context Therapeutics in a report on Friday, March 21st. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a research note on Thursday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $5.40.

Context Therapeutics Trading Down 1.5%

Shares of CNTX opened at $0.76 on Monday. The firm has a fifty day moving average price of $0.78 and a 200-day moving average price of $1.11. The firm has a market capitalization of $68.31 million, a P/E ratio of -0.84 and a beta of 2.11. Context Therapeutics has a 12-month low of $0.55 and a 12-month high of $2.75.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. MPM Bioimpact LLC purchased a new stake in shares of Context Therapeutics in the 4th quarter worth approximately $15,441,000. Franklin Resources Inc. increased its holdings in Context Therapeutics by 115.9% during the fourth quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company’s stock valued at $4,204,000 after buying an additional 2,149,392 shares during the period. Allostery Investments LP bought a new position in Context Therapeutics in the fourth quarter worth approximately $998,000. Blue Owl Capital Holdings LP lifted its holdings in Context Therapeutics by 17.5% during the fourth quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company’s stock worth $6,676,000 after buying an additional 946,638 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in Context Therapeutics by 412.8% during the fourth quarter. Renaissance Technologies LLC now owns 338,435 shares of the company’s stock worth $355,000 after buying an additional 272,435 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.